new

Get trending papers in your email inbox!

Subscribe

byAK and the research community

Mar 13

MedHalu: Hallucinations in Responses to Healthcare Queries by Large Language Models

The remarkable capabilities of large language models (LLMs) in language understanding and generation have not rendered them immune to hallucinations. LLMs can still generate plausible-sounding but factually incorrect or fabricated information. As LLM-empowered chatbots become popular, laypeople may frequently ask health-related queries and risk falling victim to these LLM hallucinations, resulting in various societal and healthcare implications. In this work, we conduct a pioneering study of hallucinations in LLM-generated responses to real-world healthcare queries from patients. We propose MedHalu, a carefully crafted first-of-its-kind medical hallucination dataset with a diverse range of health-related topics and the corresponding hallucinated responses from LLMs with labeled hallucination types and hallucinated text spans. We also introduce MedHaluDetect framework to evaluate capabilities of various LLMs in detecting hallucinations. We also employ three groups of evaluators -- medical experts, LLMs, and laypeople -- to study who are more vulnerable to these medical hallucinations. We find that LLMs are much worse than the experts. They also perform no better than laypeople and even worse in few cases in detecting hallucinations. To fill this gap, we propose expert-in-the-loop approach to improve hallucination detection through LLMs by infusing expert reasoning. We observe significant performance gains for all the LLMs with an average macro-F1 improvement of 6.3 percentage points for GPT-4.

The Troubling Emergence of Hallucination in Large Language Models -- An Extensive Definition, Quantification, and Prescriptive Remediations

The recent advancements in Large Language Models (LLMs) have garnered widespread acclaim for their remarkable emerging capabilities. However, the issue of hallucination has parallelly emerged as a by-product, posing significant concerns. While some recent endeavors have been made to identify and mitigate different types of hallucination, there has been a limited emphasis on the nuanced categorization of hallucination and associated mitigation methods. To address this gap, we offer a fine-grained discourse on profiling hallucination based on its degree, orientation, and category, along with offering strategies for alleviation. As such, we define two overarching orientations of hallucination: (i) factual mirage (FM) and (ii) silver lining (SL). To provide a more comprehensive understanding, both orientations are further sub-categorized into intrinsic and extrinsic, with three degrees of severity - (i) mild, (ii) moderate, and (iii) alarming. We also meticulously categorize hallucination into six types: (i) acronym ambiguity, (ii) numeric nuisance, (iii) generated golem, (iv) virtual voice, (v) geographic erratum, and (vi) time wrap. Furthermore, we curate HallucInation eLiciTation (HILT), a publicly available dataset comprising of 75,000 samples generated using 15 contemporary LLMs along with human annotations for the aforementioned categories. Finally, to establish a method for quantifying and to offer a comparative spectrum that allows us to evaluate and rank LLMs based on their vulnerability to producing hallucinations, we propose Hallucination Vulnerability Index (HVI). We firmly believe that HVI holds significant value as a tool for the wider NLP community, with the potential to serve as a rubric in AI-related policy-making. In conclusion, we propose two solution strategies for mitigating hallucinations.

Survey of Hallucination in Natural Language Generation

Natural Language Generation (NLG) has improved exponentially in recent years thanks to the development of sequence-to-sequence deep learning technologies such as Transformer-based language models. This advancement has led to more fluent and coherent NLG, leading to improved development in downstream tasks such as abstractive summarization, dialogue generation and data-to-text generation. However, it is also apparent that deep learning based generation is prone to hallucinate unintended text, which degrades the system performance and fails to meet user expectations in many real-world scenarios. To address this issue, many studies have been presented in measuring and mitigating hallucinated texts, but these have never been reviewed in a comprehensive manner before. In this survey, we thus provide a broad overview of the research progress and challenges in the hallucination problem in NLG. The survey is organized into two parts: (1) a general overview of metrics, mitigation methods, and future directions; and (2) an overview of task-specific research progress on hallucinations in the following downstream tasks, namely abstractive summarization, dialogue generation, generative question answering, data-to-text generation, machine translation, and visual-language generation. This survey serves to facilitate collaborative efforts among researchers in tackling the challenge of hallucinated texts in NLG.

Multimodal AI predicts clinical outcomes of drug combinations from preclinical data

Predicting clinical outcomes from preclinical data is essential for identifying safe and effective drug combinations. Current models rely on structural or target-based features to identify high-efficacy, low-toxicity drug combinations. However, these approaches fail to incorporate the multimodal data necessary for accurate, clinically-relevant predictions. Here, we introduce MADRIGAL, a multimodal AI model that learns from structural, pathway, cell viability, and transcriptomic data to predict drug combination effects across 953 clinical outcomes and 21842 compounds, including combinations of approved drugs and novel compounds in development. MADRIGAL uses a transformer bottleneck module to unify preclinical drug data modalities while handling missing data during training and inference--a major challenge in multimodal learning. It outperforms single-modality methods and state-of-the-art models in predicting adverse drug interactions. MADRIGAL performs virtual screening of anticancer drug combinations and supports polypharmacy management for type II diabetes and metabolic dysfunction-associated steatohepatitis (MASH). It identifies transporter-mediated drug interactions. MADRIGAL predicts resmetirom, the first and only FDA-approved drug for MASH, among therapies with the most favorable safety profile. It supports personalized cancer therapy by integrating genomic profiles from cancer patients. Using primary acute myeloid leukemia samples and patient-derived xenograft models, it predicts the efficacy of personalized drug combinations. Integrating MADRIGAL with a large language model allows users to describe clinical outcomes in natural language, improving safety assessment by identifying potential adverse interactions and toxicity risks. MADRIGAL provides a multimodal approach for designing combination therapies with improved predictive accuracy and clinical relevance.